Recent News for KNSA - Kiniksa Pharmaceuticals, Ltd.

Date Title
Apr 1 Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent Pericarditis
Mar 19 Kiniksa Wins FDA Nod For ARCALYST Injection therapy; Shares Pop After-Hours
Mar 19 Kiniksa price target raised at BofA; says FDA win was widely-expected
Mar 19 MP, CLVS, SOS and TNXP among premarket gainers
Mar 19 Idera suffers downgrades after trial setback; Kiniksa target upped on FDA win; and more in today’s analyst calls
Mar 19 The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs
Mar 19 27 Stocks Moving in Friday's Pre-Market Session
Mar 19 5 Stocks To Watch For March 19, 2021
Mar 18 Kiniksa wins FDA approval of Arcalyst for pericarditis; shares up 14% after-hours
Mar 18 Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis
Mar 4 The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company
Mar 3 Regeneron and Kiniksa sign commercial supply agreement for Rilonacept
Mar 2 Kiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericarditis
Feb 28 Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
Feb 23 Kiniksa Pharmaceuticals EPS misses by $0.18
Feb 23 Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity
Feb 17 3 Top Biotech Stocks With Major Catalysts Approaching
Jan 27 New Strong Sell Stocks for January 27th
Jan 11 Kiniksa Highlights Corporate Priorities and Expected 2021 Milestones
Jan 4 Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
Dec 22 Kiniksa's antibody treatment shows clinical benefit in late-stage COVID-19 study
Dec 22 Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation
Dec 18 Is KNSA A Good Stock To Buy Now?
Dec 15 Dosing underway in Kiniksa Pharma's lumpy skin disease study with vixarelimab
Dec 15 Kiniksa Commences Dosing of Vixarelimab Phase 2b Clinical Trial in Prurigo Nodularis
Back to the Main KNSA Page...